Roche Announces Strategic Collaborations to Enhance Access to Baloxavir Marboxil (Xofluza) in China

On November 7, during the 6th China International Import Expo (CIIE), Roche, for the first time, partnered with seven leading Chinese healthcare and new retail companies—Meituan Medicine, Dingdang Medicine (Beijing) Technology Co., Ltd., United Family Healthcare, Healthapple, IQVIA, Micro Medical Group (Zhejiang) Co., Ltd., and MedSci—to initiate comprehensive and in-depth collaborations in areas such as "Pediatric Influenza Prevention and Treatment" and "Medicine + Digitalization." These efforts aim to accelerate the implementation of innovative integrated influenza prevention and treatment solutions in China and further improve the accessibility of Xofluza (Baloxavir Marboxil) in the country. Additionally, Chen Yijuan, Vice President of Roche Pharma China's Specialty Medicine Division, announced for the first time at the press conference that the Baloxavir Marboxil oral suspension formulation will soon enter the Chinese market.